ReviewToxicology reports2025
Amino alkyl-alkyl/aryl sulphides (DRDE-07 and analogues) as promising cytoprotectants for sulphur and nitrogen mustards - A review.
Review in Toxicology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several antidotes and medical countermeasures were experimented for the protection of one of the notorious chemical warfare agents, the mustard gas, also known as sulphur mustard (SM). Among them, the DRDE series of compounds (amino alkyl-alkyl/aryl sulphides) showed good protection and safety in pre-clinical studies as a prophylactic antidote when administered orally. These compounds showed better protection compared to other experimented molecules, such as amifostine, N-acetylcysteine, melatonin, sodium thiosulphate, and flavonoids. Although many studies have focused on the DRDE-07 molecule, the structurally related DRDE-30 and DRDE-35 have shown better safety and protection. Among them, DRDE-30 showed the best protection for SM and nitrogen mustards, as well as against radiation, and also as a cytoprotectant for anticancer agents. In this review, all the published papers on the DRDE series of compounds are compiled and discussed, with the aim that if any one of these molecules is recommended as an oral prophylactic drug, further development would occur for a more effective, broad-spectrum cytoprotectant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.